Erenumab-Aooe
Brand Names: Aimovig
Methodology & AI Transparency ⓘ
Erenumab-Aooe Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage aimovig: is indicated for the preventive treatment of migraine in adults.
- 2 Real-world patient consensus: Real-world cohort score of 79% across 20 de-identified Erenumab-Aooe entries.
- 3 Typical cash cost range: 30-day cash pricing ranges from $185.00 discount cash to $453.25 walk-in retail (NADAC $738.5081/unit).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Erenumab-Aooe include constipation (5.8%), nausea (7.6%), headache (6.6%).
Ask our AI Specialists anything about Erenumab-Aooe
Erenumab-Aooe Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage aimovig: is indicated for the preventive treatment of migraine in adults. AIMOVIG is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults. ( 1 )
12.1 Mechanism of Action Erenumab-aooe is a human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function.
Systemic exposure to Erenumab-Aooe reflects Complete (~100%) parenteral systemic delivery for Erenumab-Aooe (70 mg/mL Injection) absorption kinetics and systemic clearance of erenumab-aooe integrates hepatic phase ii conjugation with renal filtration, sustaining receptor engagement across a Elimination kinetics span 8 to 18 hours per Erenumab-Aooe clinical pharmacology half-life window (rapid intravascular/parenteral onset within 15–45 minutes after erenumab-aooe administration response profile).
Dosing protocols (70 mg/mL Injection or 140 mg/mL Injection, Solution) balance efficacy (79.00% patient satisfaction across 20 logs) against nausea (7.6% of reports), headache (6.6% of reports), constipation (5.8% of reports), with strict avoidance in 4 contraindications aimovig is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients.; reactions have included anaphylaxis and angioedema .; aimovig is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients..
Verify medication reconciliation lists so Erenumab-Aooe is not inadvertently duplicated with another fda prescription therapeutic agent.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Erenumab-Aooe dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- 4 CONTRAINDICATIONS AIMOVIG is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients.
- Reactions have included anaphylaxis and angioedema .
- AIMOVIG is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients.
Logged Side-Effect Incidence (20 Reports)
Erenumab-Aooe Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Erenumab-Aooe)
Human clinical trial evidence for Erenumab-Aooe is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Erenumab-Aooe Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $738.5081/unit (~$22155.24/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 20 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Erenumab-Aooe Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Erenumab-Aooe RxNorm Concept ID | 2045627 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $738.5081 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 79.00% Worth It (20 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Erenumab-Aooe Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Erenumab-Aooe: FDA labeling (2026-07-14, NDC 55513-840), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Erenumab-Aooe community threads and patient logs by age, biological sex, dosage, and treatment duration.